Compass Therapeutics
CMPX
79 hedge funds and large institutions have $170M invested in Compass Therapeutics in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 14 closing their positions.
82% more capital invested
Capital invested by funds: $93.4M → $170M (+$76.2M)
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.49% less ownership
Funds ownership: 67.49% → 67% (-0.49%)
4% less funds holding
Funds holding: 82 → 79 (-3)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$2.91M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.26M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$794K |
| 4 |
Morgan Stanley
New York
|
+$262K |
| 5 |
BlackRock
New York
|
+$258K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$4.2M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.03M |
| 3 |
Millennium Management
New York
|
-$329K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$254K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$244K |
CMPX Hedge Fund Activity: Q3 2024 in Review
79 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q3 2024, worth a combined $170M — up 82% from $93.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CMPX and 11 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 29 added.
The largest buyer was Blackstone Inc, adding an estimated $2.91M. The largest seller was Janus Henderson Group, cutting an estimated $4.2M.
- 79 institutional investors held Compass Therapeutics (CMPX) as of Q3 2024, down from 82 in Q2 2024.
- Funds reported $170M of Compass Therapeutics stock for Q3 2024, up 82% quarter-over-quarter.
- 11 funds opened new Compass Therapeutics positions in Q3 2024 and 14 closed out, a net change of -3 holders.
- The largest Compass Therapeutics buyer in Q3 2024 was Blackstone Inc, an estimated $2.91M added.
- The largest Compass Therapeutics seller in Q3 2024 was Janus Henderson Group, an estimated $4.2M sold.
Based on aggregated 13F filings for Q3 2024.